
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 1/1/25**
(See policy history boxes for previous effective dates)

Title: Transplant-Small Bowel/Liver and Multivisceral

Description/Background

Solid organ transplantation offers a treatment option for patients with different types of end-stage organ failure that can be lifesaving or provide significant improvements to a patient's quality of life.¹ Many advances have been made in the last several decades to reduce perioperative complications. Available data supports improvement in long-term survival as well as improved quality of life, particularly for liver, kidney, pancreas, heart, and lung transplants. Allograft rejection remains a key early and late complication risk for any organ transplantation. Transplant recipients require life-long immunosuppression to prevent rejection. Patients are prioritized for transplant by mortality risk and severity of illness criteria developed by Organ Procurement and Transplantation Network and United Network of Organ Sharing.

SHORT BOWEL SYNDROME

Small bowel transplants are typically performed in patients with short bowel syndrome, defined as an inadequate absorbing surface of the small intestine due to extensive disease or surgical removal of a large portion of small intestine.³ In some instances, short bowel syndrome is associated with liver failure, often due to the long-term complications of total parenteral nutrition (TPN).

Intestinal transplantation (ITx) has evolved into an established therapeutic modality in the management of patients with irreversible intestinal failure (IF). It is performed for patients with short bowel syndrome or for patients with functional intestinal failure, with multivisceral transplantation reserved for those patients with associated end-stage liver disease or diffuse portomesenteric vein thrombosis. Primary indications for intestinal transplant include depletion of central venous access sites, multiple episodes of catheter-related sepsis, electrolyte disturbance, dehydration, and progressive cholestatic liver failure. Additional indications for intestinal and multivisceral transplant include diffuse portomesenteric thrombosis, malignancies limited to the abdominal compartment, and congenital motility and absorption disorders of the intestine.

Small Bowel/Liver and Multivisceral Transplant

Intestinal transplants occur less frequently than other organ transplants, with 10 or fewer patients receiving liver-intestine transplant each year from 2008 to 2019. Small bowel and liver or multi-visceral transplant is usually considered in adults and children who develop serious complications related to parenteral nutrition, including inaccessibility (e.g., due to thrombosis) of access sites, catheter-related sepsis, and cholestatic liver disease.

Treatment

These patients may be candidates for a small bowel/liver transplant or a multivisceral transplant, which includes the small bowel and liver with 1 or more of the following organs: stomach, duodenum, jejunum, ileum, pancreas, and/or colon. The type of transplantation depends on the underlying etiology of intestinal failure, quality of native organs, presence or severity of liver disease, and history of prior abdominal surgeries.⁴ A multivisceral transplant is indicated when anatomic or other medical problems preclude a small bowel/liver transplant. Complications following small bowel/liver and multivisceral transplants include acute or chronic rejection, donor-specific antibodies, infection, lymphoproliferative disorder, graft-versus-host disease, and renal dysfunction.⁵

Medical Policy Statement

A small bowel/liver or multivisceral transplant (requiring all the stomach, liver, duodenum, pancreas, and intestines to be transplanted) have been established. It may be considered a useful therapeutic option when indicated in adult and pediatric individuals with intestinal failure.

A small bowel or multivisceral transplant may be considered established for individuals for treatment of portomesenteric thrombosis.

Small bowel/liver transplant or multivisceral retransplant may be considered established for individuals following a failed primary small bowel/liver transplant or multivisceral transplant.

A modified multivisceral transplantation can involve the stomach, pancreas, large and small intestines but excludes the liver (if the recipient's liver function is normal) may be considered established when criteria are met .

A small bowel/liver transplant or multivisceral transplant is considered experimental/investigational in all other situations.

Inclusionary and Exclusionary Guidelines

Inclusions:

The individual selected for small bowel/liver, multivisceral transplant, or modified multivisceral transplant must meet the transplanting institution's protocol eligibility criteria. These criteria should include:

- Documentation of patient compliance with medical management;
- Adequate cardiopulmonary status; **and**

- Intestinal failure*; **or**
- Portomesenteric thrombosis.

*Intestinal failure is characterized by loss of absorption and the inability to maintain protein-energy, fluid, electrolyte, or micronutrient balance) who have been managed with long-term total parenteral nutrition (TPN) and who have developed evidence of impending end-stage liver failure.

Potential Contraindications for Transplant/Retransplant:

Note: Final patient eligibility for transplant is subject to the judgment and discretion of the requesting transplant center.

Potential contraindications represent situations where proceeding with transplant is not advisable in the context of limited organ availability. Contraindications may evolve over time as transplant experience grows in the medical community. Clinical documentation supplied to the health plan should demonstrate that attending staff at the transplant center have considered all contraindications as part of their overall evaluation of potential organ transplant recipients and have decided to proceed.

- Known current malignancy, including metastatic cancer
- Recent malignancy with high risk of recurrence
- History of cancer with a moderate risk of recurrence
- Systemic disease that could be exacerbated by immunosuppression
- Untreated systemic infection making immunosuppression unsafe, including chronic infection
- Other irreversible end-stage disease not attributed to intestinal failure
- Psychosocial conditions or chemical dependency affecting ability to adhere to therapy

Small Bowel/Liver Specific

Evidence of intolerance of total parenteral nutrition (TPN) includes, but is not limited to, multiple and prolonged hospitalizations to treat TPN-related complications, or the development of progressive but reversible liver failure. In the setting of progressive liver failure, small bowel transplant may be considered a technique to avoid end-stage liver failure related to chronic TPN, thus avoiding the necessity of a multivisceral transplant.

Exclusions:

- Small bowel-liver-multivisceral transplants are considered investigational in all other situations.

All transplants must be prior authorized through the Human Organ Transplant Program.

*Please note there are individual policies for each of these organs (small bowel, liver) which contain more detailed information.

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure)*

Established codes:

44120 44121 44132 44133 44135 44136

44715	44720	44721	44799	47133	47135
47399	47140	47141	47142	47143	47144
47145	47146	47147	S2053	S2054	S2055

Other codes (investigational, not medically necessary, etc.):

N/A

Rationale

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function-including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

TRANSPLANTATION OF SMALL BOWEL/LIVER OR MULTIVISCERAL ORGANS

Clinical Context and Therapy Purpose

The purpose of small bowel and liver transplant alone or multivisceral transplant in patients who have intestinal failure and evidence of impending end-stage liver failure is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following **PICOs** were used to select literature to inform this review.

Populations

The relevant population of interest is individuals with intestinal failure and evidence of impending end-stage liver failure.

Interventions

The therapy being considered is small bowel and liver transplant alone or multivisceral transplant.

Comparators

The following practices are currently being used to make decisions about intestinal failure and evidence of impending end-stage liver failure: medical management and parenteral nutrition.

Outcomes

The general outcomes of interest are overall survival (OS), morbid events, and treatment-related mortality and morbidity.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Within each category of study design, studies with larger sample sizes and longer duration were preferred.
- Studies with duplicative or overlapping populations were excluded.

Systematic Reviews

A 1999 TEC Assessment focused on multivisceral transplantation and offered the following conclusions: Multivisceral transplantation in patients with small bowel syndrome, liver failure, and/or other gastrointestinal problems such as pancreatic failure, thromboses of the celiac axis and the superior mesenteric artery, or pseudo-obstruction affecting the entire gastrointestinal tract associated with poor patient and graft survival. Pediatric and adult patients have a similar 2- and 5-year survival of 33–50%. However, without this procedure, it is expected that these patients would face 100% mortality.⁶

Registry Studies and Case Series

The published literature consists of a registry study and case series, mainly reported by single centers in the United States and Europe. Tables 1 and 2 summarize the characteristics and results of the publications respectively.

Reasons for transplantations were mainly short bowel syndrome. Other reasons included congenital enteropathies and motility disorders. Most common outcomes reported were survival rates and weaning off total parenteral nutrition (TPN). Several studies have presented survival rates by type of transplantation, while others have combined all types of transplants when reporting survival rates. When rates were reported by type of transplant, isolated transplantations had higher survival rates than multivisceral transplants (see Table 2).

Several investigators have reported higher survival rates in transplants conducted more recently than those conducted earlier.⁷⁻¹⁰ Reasons for improved survival rates in more recent years have been attributed to the development of more effective immunosuppressive drugs and the learning curve for the complex procedure.

Authors of these publications, as well as related reviews, have observed that while outcomes have improved over time, recurrent and chronic rejection and complications of

immunosuppression continue to be obstacles to long-term survival. A separate discussion of complications follows the evidence tables.

Table 1. Summary of Key Registry Studies and Case Series Characteristics for Transplants

Author (Year)	Location	N	Median Age (Range), Y	Interventions	Follow-up (Range)	
				Treatment	n	
Raghu et al (2019)	International	2080	2.5 (1.1-6.3)	<ul style="list-style-type: none"> Isolated IT Combined liver IT Multivisceral Graft (including modified [intestine and stomach without liver] and full [intestine, stomach, and liver]) 	725 966 389	5 y
Lacaille et al (2017)	France	110	5.3 (0.4-19)	<ul style="list-style-type: none"> Isolated IT Combined liver IT Multivisceral graft 	45 60 5	Of 55 alive: <ul style="list-style-type: none"> 17 at <5 y 17 at 5-10 y 21 at ≥10 y
Garcia Aroz et al (2017)	United States	10	1.5 (0.7-13)	<ul style="list-style-type: none"> Isolated IT Combined liver IT 	7 3	6/7 alive at follow-up ≥ 10 y
Dore et al (2016)	United States	30	0.2 (0.1-18)	<ul style="list-style-type: none"> Isolated IT Combined liver IT Multivisceral graft 	6 6 18	28 (4-175) mo
Rutter et al (2016)	United Kingdom	60	1.8 (0-8)	<ul style="list-style-type: none"> Isolated IT Multivisceral graft Modified multivisceral 	16 35 9	21.3 (0-95) mo
Lauro et al (2014)	Italy	46	34 (NR)	<ul style="list-style-type: none"> Isolated IT Combined liver IT Multivisceral graft 	34 6 6	51.3 mo
Varkey et al (2013)	Sweden	20	Adults: 44 (20-67) Children: 6 (0.5-13)	<ul style="list-style-type: none"> Isolated IT Combined liver IT Multivisceral graft 	4 1 15	NR
Mangus et al (2013)	United States	100	Adults: 48 (NR to 66) Children: 1 (0.6 to NR)	<ul style="list-style-type: none"> Multivisceral graft Modified multivisceral 	84 16	25 mo

IT: intestinal transplantation; NR: not reported.

^a Living donors

Table 2. Summary of Key Case Series Results for Transplantations

Author (Year)	Interventions	Survival	Off TPN	
	Treatment	n		
Raghu et al (2019)	<ul style="list-style-type: none"> Isolated It Combined liver IT Multivisceral graft (including modified [intestine and stomach 	725 966 389	All transplantations combined: <ul style="list-style-type: none"> Patient survival: 72.7% at 1 y; 57.2% at 5 y Graft survival: 66.1% at 1 y; 47.8% at 5 yy 	NR

	without liver] and full [intestine, stomach, and liver])			
Lacaille et al (2017)	<ul style="list-style-type: none"> • Isolated IT • Combined liver IT • Multivisceral graft 	45 60 5	<ul style="list-style-type: none"> • 59% at 10 y; 54% at 18 y • 48% at 10 y • NR 	All treatments combined: 73% at last follow-up
Garcia Aroz et al (2017)	<ul style="list-style-type: none"> • Isolated IT • Combined liver IT 	7 3	<ul style="list-style-type: none"> • All transplantations combined: 70% 	All treatments combined: 100% at last follow-up
Dore et al (2016)	<ul style="list-style-type: none"> • Isolated IT • Combined liver IT • Multivisceral graft 	6 6 18	<ul style="list-style-type: none"> • 83% at 9 y • 33% at 10 y • 67% at 2.5 y 	All treatments combined: 71% in 31 d and 62% at last follow-up
Rutter et al (2016)	<ul style="list-style-type: none"> • Isolated IT • Multivisceral graft • Modified multivisceral 	16 35 9	<ul style="list-style-type: none"> • 92% at 1 y; 37% at 5 y • 71% at 1 y; 33% at 5 y • 85% at 1 y, 65% at 5y 	NR
Lauro et al (2014)	<ul style="list-style-type: none"> • Isolated IT • Combined liver IT • Multivisceral graft 	34 6 6	All transplantations combined: <ul style="list-style-type: none"> • 77% at 1 y • 58% at 3 y • 53% at 5 y • 37% at 10 y 	NR
Varkey et al (2013)	<ul style="list-style-type: none"> • Isolated IT • Combined liver IT • Multivisceral graft 	4 1 15	All transplantations combined: <ul style="list-style-type: none"> • 78% at 1 year • 50 % at 5 y 	NR
Mangus et al (2013)	<ul style="list-style-type: none"> • Multivisceral graft • Modified multivisceral 	84 16	All transplantations combined: <ul style="list-style-type: none"> • 72% at 1 y • 57% at 5 y 	NR

IT: intestinal transplantation; NR: not reported; TPN: total parenteral nutrition.

^a Living donors

Complications

Several case series have focused on complications after small bowel and multivisceral transplantation. For example, Spence et al (2019) performed a retrospective chart review of intra-abdominal and bloodstream infection in adults undergoing intestinal or multivisceral transplant at a single center in the U.S.¹⁷ A total of 103 adult patients (median age, 44 years) were included who received 106 intestinal or multivisceral transplants between 2003 and 2015. Intra-abdominal infection occurred in 46 (43%) patients, and concurrent bloodstream infection occurred in 6 (13%) patients. The median time to first intra-abdominal infection was 23 days (interquartile range, 10-48). All-cause mortality was not significantly different between patients with versus without intra-abdominal infections (p=0.654).

in 2016, Nagai et al reported on cytomegalovirus (CMV) infection after intestinal or multivisceral transplantation at a single center in the United States.¹⁸ A total of 210 patients had an intestinal transplant, multivisceral transplant, or modified multivisceral transplant between January 2003 and June 2014. Median length of follow-up was 2.1 years. Thirty-four (16%) patients developed CMV infection a median of 347 days after transplantation. Nineteen patients had tissue invasive CMV disease. In a report from another U.S. center, 16 (19%) of 85 patients undergoing intestinal or multivisceral transplantation developed CMV infection a mean of 139 days (range, 14-243 days) postoperatively.¹⁹

In 2016, Wu et al investigated the incidence and risk factors of acute antibody-mediated rejection (ABMR) among patients undergoing intestinal transplantation (N=175).²⁰ All patients were 25 years of age. Acute ABMR was diagnosed by clinical evidence; histologic evidence of tissue damage; focal or diffuse linear C4d deposition; and circulating anti-human leukocyte antigen antibodies. Of the 175 intestinal transplants, 58% were liver-free grafts, 36% included

a liver graft, and 6.3% were retransplantations. Eighteen cases of acute ABMR were identified- 14 (14%) among the patients undergoing first liver-free transplantation, 2 (3%) among patients undergoing liver/small bowel transplantations, and 2 (18%) among the patients undergoing retransplantation. Graft failure occurred in 67% of patients with acute ABMR. The presence of a donor-specific antibody and a liver-free graft were associated with the development of acute ABMR.

In a 2016 series by Cromvik et al, 5 (19%) of 26 patients were diagnosed with graft-versus-host disease (GVHD) after intestinal or multivisceral transplantation.²¹ Risk factors for GVHD were: malignancy as a cause of transplantation; neoadjuvant chemotherapy; or brachytherapy before transplantation.

In addition, a 2012 article by Florescu et al retrospectively reported on bloodstream infections among 98 children younger than age 18 years with small bowel/combined organ transplants.²² Seventy-seven (79%) patients underwent small bowel transplant in combination with a liver, kidney or kidney-pancreas, and 21 had an isolated small bowel transplant. After a median follow-up of 52 months, 58 (59%) patients remained alive. The 1-year survival rate was similar in patients with combined small bowel transplant (75%) and those with isolated small bowel transplant (81%). In the first year after transplantation, 68 patients (69.4%) experienced at least one episode of bloodstream infection. The 1-year survival rate for patients with bloodstream infections was 72% compared to 87% in patients without bloodstream infections (p-value= 0.056 for difference in survival in patients with and without bloodstream infections).

In 2011 Wu et al reported on 241 patients who underwent intestinal transplantation.²³ Of these, 147 (61%) had multivisceral transplants, 65 (27%) had small bowel transplants, and 29 (12%) had small bowel/liver transplants. There were 151 (63%) children and 90 (37%) adults. Twenty-two (9%) patients developed graft-versus-host disease (GVHD). Children younger than 5 years old were more likely to develop this condition; the incidence in this age group was 16 (13.2%) of 121 compared with 2 (6.7%) of 30 in children between 5 and 18 years and 9 (4.4%) of 90 in adults older than 18 years.

HIV-Positive Transplant Recipients

Solid organ transplant for patients who are HIV-positive was historically controversial, due to the long-term prognosis for HIV positivity and the impact of immunosuppression on HIV disease. No studies reporting on outcomes in HIV-positive patients who received small bowel and liver or multivisceral transplants were identified in literature reviews.

Current OPTN policy permits HIV-positive transplant candidates.²⁴

The British HIV Association and the British Transplantation Society (2017) updated their guidelines on kidney transplantation in patients with HIV disease.²⁵ These criteria may be extrapolated to other organs:

- Adherent with treatment, particularly antiretroviral therapy
- CD4 count greater than 100 cells/mL (ideally >200 cells/mL) for at least 3 months
- Undetectable HIV viremia (<50 HIV-1 RNA copies/mL) for at least 6 months
- No opportunistic infections for at least 6 months
- No history of progressive multifocal leukoencephalopathy, chronic intestinal cryptosporidiosis, or lymphoma.

Section Summary: Transplantation of Small Bowel-Liver or Multivisceral Organs

Intestinal transplantation procedures are infrequently performed and only one registry study and relatively small case series, generally single center, are available. For patients experiencing significant complications from TPN, which can lead to liver failure and repeated infections, this literature has shown a reasonably high post-transplant survival rates in patients who have a high probability of death without treatment. Guidelines and U.S. federal policy no longer view HIV infection as an absolute contraindication for solid organ transplantation.

Modified Multivisceral Transplantation

In 2007, Matsumoto and Fishbein discussed a modified multivisceral technique where the native spleen and pancreas were preserved with venous outflow through a native portocaval shunt, and native pancreatic exocrine drainage was established to the donor jejunum.²⁶ According to the authors, the risk of transplant pancreatic insufficiency, posttransplant lymphoproliferative disorder, and postsplenectomy sepsis was avoided. This new modification of multivisceral transplantation allows pancreaticosplenic preservation while facilitating stomach replacement for those patients requiring intestinal replacement therapy. It represents another step towards minimizing morbidities associated with these lifesaving transplants.

Cruz et al (2010) reported on a modification of a multivisceral transplant operation where the donor liver was spared, and the native spleen along with pancreaticoduodenal complex was preserved.²⁷ Thirty-six modified multivisceral grafts that include stomach, duodenum, pancreas, and intestine were given to 30 adults and six children. Leading causes of intestinal failure were pseudo-obstruction and Gardner's syndrome. Native spleen was preserved in 24 (67%) recipients along with pancreaticoduodenal complex in 18 (50%). Immunosuppression was tacrolimus-based, and recipient preconditioning was utilized in 80% of patients. Patient survival was 94% at 1 year and 75% at 5 years with graft survival of 91% and 51%; respectively. With mean follow-up of 51 ± 35 months, full nutritional autonomy was achieved in 89% of current survivors with no single example of disease recurrence. Preservation of native spleen was associated with increased survival and reduced risk of post-transplant lymphoproliferative disorder (PTLD), life-threatening infections, and GVHD with no significant impact on graft loss due to rejection. Concomitant preservation of pancreaticoduodenal complex eliminated risks of biliary complications and glucose intolerance.

Vianna et al (2012) evaluated outcomes of multivisceral transplantation (MVT) in the setting of diffuse thrombosis of the portomesenteric venous system.²⁸ A database of intestinal transplant patients was maintained with prospective analysis of outcomes. The diagnosis of diffuse postmesenteric thrombosis (PMT) was established with dual-phase abdominal computed tomography or magnetic resonance imaging with venous reconstruction. Twenty-five patients with grade IV PMT received 25 MVT. Eleven patients underwent simultaneous cadaveric kidney transplantation. Biopsy-proven acute cellular rejection was noted in 5 recipients, which was treated successfully. With a median follow-up of 2.8 years, patient and graft survival were 80%, 72%, and 72% at 1, 3, and 5 years, respectively. To date, all survivors have good graft function without any signs of residual/recurrent features of portal hypertension.

In a retrospective case review, Mangus et al (2013) described multivisceral transplantation including the simultaneous transplantation of multiple abdominal viscera including the stomach, duodenum, pancreas, and small intestine, with (multivisceral transplant, MVT) or without the liver (modified MVT, MMVT).²⁹ During the study period, 95 patients received 100 transplants including 84 MVT and 16MMVT. There were 19 patients who received a simultaneous kidney graft. There were 24 pediatric and 76 adult recipients (range 7 months to 66 years). Indications included intestinal failure alone, intestinal failure with cirrhosis, complete

portal mesenteric thrombosis, slow-growing central abdominal tumors, intestinal pseudo-obstruction, and frozen abdomen. All patients received antibody-based induction immunosuppression with calcineurin inhibitor-based maintenance immunosuppression. At a median mortality adjusted follow-up of 25 months, 1- and 3-year patient survival is 72 % and 57 %. There was a learning curve with this complex procedure resulting in a 48 % patient survival during the period from 2004 to 2007, followed by a 70 % patient survival during the period from 2008 to 2010. Post-transplant complications included rejection (50 % MMVT and 17 % MVT), infection (>90 % first year), graft versus host disease (13 %), and post-transplant lymphoproliferative disorder (PTLD) (5 %).

Benedetto et al (2024) identified predictors of adverse outcomes after LT in patients with nonmalignant portal vein thrombosis (PVT) and sought to improve donor to recipient matching by analyzing the results of the Italian cohort of LT recipients.³⁰ Seven hundred fourteen patients were screened and 698 met the inclusion criteria. The analysis reports the results of 568 patients that fulfilled the criteria to enter the composite outcome analysis. Overall, 156 patients (27.5%) developed the composite outcome. PVT stage 3/4 at transplant and need for any surgical correction of PVT are independent predictors of the composite outcome occurrence. When stratified by PVT grade, overall survival at 1-year ranges from 89.0% with PVT grade 0/1 to 67.4% in patients with PVT grade 3/4 at LT (P <0.001). Nevertheless, patients with severe PVT can improve their survival when identified risk factors are not present.

RETRANSPLANTATION OF SMALL BOWEL AND LIVER OR MULTIVISCERAL ORGANS

Clinical Context and Therapy Purpose

The purpose of small bowel and liver retransplant alone or multivisceral retransplant in patients who have a failed small bowel and liver or multivisceral transplant without contraindications for retransplant is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following **PICOs** were used to select literature to inform this review.

Populations

The relevant population of interest is individuals with a failed small bowel and liver or multivisceral transplant without contraindications for retransplant.

Interventions

The therapy being considered is small bowel and liver retransplant alone or multivisceral retransplant.

Comparators

The following practices are currently being used to make decisions about failed small bowel and liver or multivisceral transplant when there are no contraindications for retransplant: medical management and parenteral nutrition.

Outcomes

The general outcomes of interest are OS, morbid events, treatment-related mortality, and treatment-related morbidity.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Within each category of study design, studies with larger sample sizes and longer duration were preferred.
- Studies with duplicative or overlapping populations were excluded.

Case Series

Evidence for the use of retransplantation to treat individuals who have failed intestinal transplantations includes several case series, mostly from single institutions. One case series analyzed records from the United Network for Organ Sharing database.⁹ Among the case series described in Table 3, reasons for retransplantations include: acute rejection, chronic rejection, CMV, liver failure, lymphoproliferative disorder, and graft dysfunction. Survival rates for retransplantations are listed in Table 4.

Table 3. Summary of Key Case Series Characteristics for Retransplants

Author (Year)	Location	N	Median Age (Range), y	Interventions	Follow-Up, (Range), mo	
				Treatment	n	
Ekser et al (2018)	U.S.	18 ^b	27.0 (17.4) ^a (0.9 to 57)	<ul style="list-style-type: none"> • Isolated IT • Modified MVT • Multivisceral graft 	1 1 16	NR
Lucaille et al (2017)	France	10	13 (5-16)	<ul style="list-style-type: none"> • Isolated IT • Combined liver IT 	3 7	4
Desai et al (2012)	United States	72 adults 77 children	NR	Adults: <ul style="list-style-type: none"> • Isolated IT • Combined liver IT Children: <ul style="list-style-type: none"> • Isolated IT • Combined liver IT 	41 31 28 49	NR
Abu-Elmage et al (2009)	United States	47	NR	<ul style="list-style-type: none"> • Isolated IT • Combined liver IT • Multivisceral graft 	31 7 9	NR
Mazariegos et al (2008)	United States	14	9.4 (3.2-22.7)	<ul style="list-style-type: none"> • Isolated IT • Combined liver • Multivisceral graft 	1 3 10	55.9

IT: intestinal transplantation; NR: not reported

^a Mean (standard deviation).

^b Of a cohort of 218 transplant or retransplant procedures.

Table 4. Summary of Key Case Series Results for Retransplantations

Author (Year)	Interventions	Survival	Off TPN
	Treatment	n	
Ekser et al (2018)	<ul style="list-style-type: none"> • Isolated IT 	1	Graft survival: NR

	<ul style="list-style-type: none"> Modified MVT Multivisceral graft 	1 16	<ul style="list-style-type: none"> 71% at 1 y; 56% at 3 y; 44% at 5 y Patient survival <ul style="list-style-type: none"> 71% at 1 y; 47% at 3 y; 37% at 5 y 	
Lucaille et al (2017)	<ul style="list-style-type: none"> Isolated IT Combined liver IT 	3 7	All transplantations combined: 30% at last follow-up	NR
Desai et al (2012)	Adults: <ul style="list-style-type: none"> Isolated IT Combined liver IT Children: <ul style="list-style-type: none"> Isolated IT Combined liver IT 	41 31 28 49	Adults: <ul style="list-style-type: none"> 80% at 1 y; 47% at 3 y; 29% at 5 y 53% at 1 y; 56% at 3 y; 47% at 5 Y 	NR
Abu-Elmage et al (2009)	<ul style="list-style-type: none"> Isolated IT Combined liver IT Multivisceral graft 	31 7 9	All transplantations combined: <ul style="list-style-type: none"> 69% at 1 y 47% at 5 y 	NR
Mazariegos et al (2008)	<ul style="list-style-type: none"> Isolated IT Combined liver Multivisceral graft 	1 3 10	All transplantations combined: <ul style="list-style-type: none"> 71% at last follow-up 	100%

IT: intestinal transplantation; NR: not reported; TPN: total parenteral nutrition.

Section Summary: Retransplantation of Small Bowel/Liver or Multivisceral Organs

Evidence for retransplantations derives mostly from single-center case series, though 1 series used records from the United Network for Organ Sharing database. Although limited in quantity, the available follow-up data after retransplantation have suggested reasonably high survival rates after small bowel and liver transplants and multivisceral retransplantation in patients who continue to meet criteria for transplantation.

SUMMARY OF EVIDENCE

For individuals who have intestinal failure and evidence of impending end-stage liver failure who receive a small bowel and liver transplant alone or multivisceral transplant, the evidence includes a registry study and a limited number of case series. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. These procedures are infrequently performed and only relatively small case series, generally single center, are available. Results from the available literature have shown reasonably high postprocedural survival rates. Given exceedingly poor survival rates without transplantation of patients who have exhausted other treatments, evidence of postoperative survival from uncontrolled studies is sufficient to demonstrate that small bowel/liver and multivisceral transplantation provides a survival benefit in appropriately selected patients. Transplantation is contraindicated for patients in whom the procedure is expected to be futile due to comorbid disease or in whom post transplantation care is expected to significantly worsen comorbid conditions. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have intestinal failure and evidence of other multivisceral failure, the evidence includes literature describing a modified multivisceral transplantation procedure, and a retrospective case review. This modified technique represents another step towards minimizing morbidities associated with lifesaving transplants and decreasing risks of biliary complications and glucose intolerance. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have a failed small bowel and liver or multivisceral transplant without contraindications for retransplant who receive a small bowel and liver retransplant alone or multivisceral retransplant, the evidence includes case series. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. Although limited in quantity, the available post retransplantation data has suggested reasonably high survival rates. Given exceedingly poor survival rates without retransplantation of patients who have exhausted other treatments, evidence of postoperative survival from uncontrolled studies is sufficient to demonstrate that retransplantation provides a survival benefit in appropriately selected patients. Retransplantation is contraindicated for patients in whom the procedure is expected to be futile due to comorbid disease or in whom post transplantation care is expected to significantly worsen comorbid conditions. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

PRACTICE GUIDELINES AND POSITION STATEMENTS

American Gastroenterological Association

In 2003, the American Gastroenterological Association published a position statement on short bowel syndrome and intestinal transplantation.³¹ The statement noted that only patients with life-threatening complications due to intestinal failure or long-term total parenteral nutrition have undergone intestinal transplantation. The statement recommended the following Medicare-approved indications, pending availability of additional data:

- Impending liver failure
- Thrombosis of major central venous channels
- Frequent central line associated sepsis
- Frequent severe dehydration.

The AGA published an expert review update in 2022.³¹ The update made the same statements as the 2003 position statement in their best practice advice for referral for intestinal transplantation.

American Society of Transplantation

In 2001, the American Society of Transplantation issued a position paper on indications for pediatric intestinal transplantation.³² The Society listed the following disorders in children as being potentially treatable by intestinal transplantation: short bowel syndrome, defective intestinal motility, and impaired enterocyte absorptive capacity. Contraindications for intestinal transplant to treat pediatric patients with intestinal failure are similar to those of other solid organ transplants: profound neurologic disabilities, life threatening comorbidities, severe immunologic deficiencies, nonresectable malignancies, autoimmune diseases, and insufficient vascular patency.

Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov did not identify any ongoing or unpublished trials that would likely influence this policy.

Government Regulations **National/Local:**

Medicare will cover intestinal transplantation for the purposes of restoring intestinal function in patients with irreversible intestinal failure only when performed for patients who have failed TPN and only when performed in centers that meet approved criteria.³¹The criteria for approval of centers will be based on an annual volume of 10 intestinal transplants per year with a 1-year actuarial survival of 65% (these criteria were reviewed again in 2006 and upheld).

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

- Transplant-Heart
 - Transplant-Heart-Lung (Combined)
 - Transplant- Small Bowel (Isolated)
 - Transplant-Heart and Kidney (Combined)
 - Transplant-Liver
 - Transplant-Lung and Lobar Lung
 - Transplant-Lung-Double Lung and Liver (Combined)
 - Transplant-Pancreas
-

References

1. Black CK, Termanini KM, Aguirre O, et al. Solid organ transplantation in the 21 st century. *Ann Transl Med.* Oct 2018; 6(20): 409. PMID 30498736
2. Organ Procurement and Transplantation Network (OPTN). National Data. <https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/>. Accessed August 2022.
3. Sulkowski JP, Minneci PC. Management of short bowel syndrome. *Pathophysiology.* Feb 2014; 21(1): 111-8. PMID 24341969
4. Bharadwaj S, Tandon P, Gohel TD, et al. Current status of intestinal and multivisceral transplantation. *Gastroenterol Rep (Oxf).* Feb 2017; 5(1): 20-28. PMID 28130374
5. Loo L, Vrakas G, Reddy S, et al. Intestinal transplantation: a review. *Curr Opin Gastroenterol.* May 2017; 33(3): 203-211. PMID 28282321
6. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Small bowel transplants in adults and multivisceral transplants in adults and children. *TEC Assessments.* 1999;Volume 14:Tab 9.
7. Mangus RS, Tector AJ, Kubal CA, et al. Multivisceral transplantation: expanding indications and improving outcomes. *J Gastrointest Surg.* Jan 2013; 17(1): 179-86; discussion p.186-7. PMID 23070622
8. Abu-Elmagd KM, Costa G, Bond GJ, et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. *Ann Surg.* Oct 2009; 250(4): 567-81. PMID 19730240
9. Desai CS, Khan KM, Gruessner AC, et al. Intestinal retransplantation: analysis of Organ Procurement and Transplantation Network database. *Transplantation.* Jan 15 2012; 93(1): 120-5. PMID 22113492
10. Raghu VK, Beaumont JL, Everly MJ, et al. Pediatric intestinal transplantation: Analysis of the intestinal transplant registry. *Pediatr Transplant.* Dec 2019; 23(8): e13580. PMID 31531934

11. Lacaille F, Irtan S, Dupic L, et al. Twenty-eight years of intestinal transplantation in Paris: experience of the oldest European center. *Transpl Int.* Feb 2017; 30(2): 178-186. PMID 27889929
12. Garcia Aroz S, Tzvetanov I, Hetterman EA, et al. Long-term outcomes of living-related small intestinal transplantation in children: A single-center experience. *Pediatr Transplant.* Jun 2017; 21(4). PMID 28295952
13. Dore M, Junco PT, Andres AM, et al. Surgical Rehabilitation Techniques in Children with Poor Prognosis Short Bowel Syndrome. *Eur J Pediatr Surg.* Feb 2016; 26(1): 112-6. PMID 26535775
14. Rutter CS, Amin I, Russell NK, et al. Adult Intestinal and Multivisceral Transplantation: Experience From a Single Center in the United Kingdom. *Transplant Proc.* Mar 2016; 48(2): 468-72. PMID 27109980
15. Lauro A, Zanfi C, Dazzi A, et al. Disease-related intestinal transplant in adults: results from a single center. *Transplant Proc.* Jan- Feb 2014; 46(1): 245-8. PMID 24507060
16. Varkey J, Simren M, Bosaeus I, et al. Survival of patients evaluated for intestinal and multivisceral transplantation – the Scandinavian experience. *Scand J Gastroenterol.* Jun 2013; 48(6): 702-11. PMID 23544434
17. Spence AB, Natarajan M, Fogleman S, et al. Intra-abdominal infections among adult intestinal and multivisceral transplant recipients in the 2-year post-operative period. *Transpl Infect Dis.* Feb 2020; 22(1): e13219. PMID 31778012
18. Nagai S, Mangus RS, Anderson E, et al. Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation: A Single-Center Experience With 210 Cases. *Transplantation.* Feb 2016; 100(2): 451-60. PMID 26247555
19. Timpone JG, Yimen M, Cox S, et al. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients. *Transpl Infect Dis.* Apr 2016; 18(2): 202-9. PMID 26853894
20. Wu GS, Cruz RJ, Cai JC. Acute antibody-mediated rejection after intestinal transplantation. *World J Transplant.* Dec 24 2016; 6(4): 719-728. PMID 28058223
21. Cromvik J, Varkey J, Herlenius G, et al. Graft-versus-host Disease After Intestinal or Multivisceral Transplantation: A Scandinavian Single-center Experience. *Transplant Proc.* Jan-Feb 2016; 48(1): 185-90. PMID 26915866
22. Florescu DF, Qiu F, Langnas AN, et al. Bloodstream infections during the first year after pediatric small bowel transplantation. *Pediatr Infect Dis J.* Jul 2012; 31(7): 700-4. PMID 22466325
23. Wu G, Selvaggi G, Nishida S, et al. Graft-versus-host disease after intestinal and multivisceral transplantation. *Transplantation.* Jan 27 2011; 91(2): 219-24. PMID 21076376
24. Organ Procurement and Transplantation Network (OPTN). Organ Procurement and Transplantation Network Policies. 2022; https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf. Accessed August 2023.
25. Working Party of the British Transplantation Society. Kidney and Pancreas Transplantation in Patients with HIV. Second Edition (Revised). British Transplantation Society Guidelines. Macclesfield, UK: British Transplantation Society; 2017.
26. Matsumoto C, and Fishbein T. Modified multivisceral transplantation with splenopancreatic preservation. *Transplantation.* Jun 2007;83(2):234-236.
27. Cruz RJ, Costa G, Bond G, et al. Modified “liver-sparing” multivisceral transplant with preserved native spleen, pancreas, and duodenum: technique and long-term outcome. *J Gastrointest Surg.* Nov 2010; 14(11):1709-1721.
28. Vianna RM, Mangus RS, Kubal C, et al. Multivisceral transplantation for diffuse portomesenteric thrombosis. *Ann Surg.* Jun 2012; 255(6):1144-1150.

29. Mangus R, Tector AJ, Kubal CA, et al. Multivisceral transplantation: expanding indications and improving outcomes. *J Gastrointest Surg.* Jan 2013;17(1):186-187.
30. Benedetto FD, Magistri P, Sandro SD, et al. Portal vein thrombosis and liver transplantation: management, matching, and outcomes. A retrospective multicenter cohort study. *Int J Surg.* May 2024; 110(5): 2874-2882.
31. Ekser B, Kubal CA, Fridell JA, et al. Comparable outcomes in intestinal retransplantation: Single-center cohort study. *Clin Transplant.* Jul 2018; 32(7): e13290. PMID 29782661
32. Mazariegos GV, Soltys K, Bond G, et al. Pediatric intestinal retransplantation: techniques, management, and outcomes. *Transplantation.* Dec 27 2008; 86(12): 1777-82. PMID 19104421
33. American Gastroenterological Association. American Gastroenterological Association medical position statement: short bowel syndrome and intestinal transplantation. *Gastroenterology.* Apr 2003; 124(4): 1105-10. PMID 12671903
34. Kaufman SS, Atkinson JB, Bianchi A, et al. Indications for pediatric intestinal transplantation: a position paper of the American Society of Transplantation. *Pediatr Transplant.* Apr 2001; 5(2): 80-7. PMID 11328544
35. Center for Medicare & Medicaid Services. National Coverage Determination (NCD) for Intestinal and Multi- Visceral Transplantation (260.5). 2006; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=280&ncdver=2&CoverageSelection=National&Keyword=intestinal&KeywordLookUp=Title&KeywordSearchType=And&generalError=Thank+you+for+your+interest+in+the+Medicare+Coverage+Database.+You+may+only+view+the+page+you+attempted+to+access+via+normal+usage+of+the+Medicare+Coverage+Database.&bc=gAAAACA AAAAAA%3d%3d&>. Accessed September 2024.
36. Blue Cross Blue Shield Association. Small Bowel/Liver and Multivisceral Transplant. Medical Policy Reference Manual. Policy #7.03.05, Issue 6:2013, original policy date 12/1/95, last review date September 2024.
37. HAYES Directory Assessment. Small Bowel, Small Bowel-Liver, and Multivisceral Transplantation. Lansdale, PA: HAYES, Inc. February 28, 2005, updated April 7, 2009, archived March 28 2005.

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through September 2024, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
7/1/12	4/10/12	5/18/12	The consolidated policy "small bowel of Small Bowel/Liver-Multivisceral Transplants" was split into two separate policies: Small Bowel Transplant- Isolated and this policy, Small Bowel/Liver-Multivisceral Transplant. Updated description, rationale and references to mirror BCBSA policies.
11/1/13	8/22/13	8/27/13	Routine maintenance Added "small bowel/liver transplant or multivisceral retransplant after a failed primary small bowel/liver transplant or multivisceral transplant" to the inclusions. Removed procedure codes 44135-44136.
3/1/15	12/12/14	12/29/14	Routine maintenance. No substantive changes to policy. Statement added that procedure is investigational in all other situations.
7/1/16	4/19/16	4/19/16	Routine maintenance. No change in policy statement
7/1/17	4/18/17	4/18/17	Updated rationale and added references # 2, 6, 7, 9, 14 and 20. Deleted references 1 and 10. Deleted code 47136, added code 47399. No change in policy status.
7/1/18	4/17/18	4/17/18	Updated rationale section, added references # 7-9 and 15. No change in policy status.
7/1/19	4/16/19		Routine policy maintenance. No change in policy status.
7/1/20	4/14/20		Routine policy maintenance. No change in policy status.
7/1/21	4/20/21		Routine policy maintenance. Added reference #9. No change in policy status.
7/1/22	4/19/22		Routine policy maintenance, no change in policy status.
1/1/23	10/18/22		Added modified multivisceral transplant to MPS as established,

			updated rationale section, added references 2 and 26-28. No change in policy status.
1/1/24	10/17/23		Routine policy maintenance, no change in policy status. Vendor managed: N/A (ds)
1/1/25	10/15/24		Changes made to MPS and inclusion/exclusion sections. Title change. Updated rationale added references 28 and 30. No change in status. Vendor managed: N/A (ds)

Next Review Date: 4th Qtr. 2025

Joint BCBSM/BCN Consolidated Medical Policy History (Small Bowel or Small Bowel/Liver or Multivisceral Transplant)

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
6/13/02	6/13/02	6/13/02	Joint medical policy established
11/8/04	11/8/04	12/6/04	Routine maintenance
11/15/05	11/15/05	9/26/05	Routine maintenance
9/1/06	7/10/06	7/6/06	Routine maintenance
9/1/07	7/1/07	8/26/06	Routine maintenance
11/1/08	8/19/08	10/30/08	Routine maintenance

No further review will be done on the consolidated policy; refer to separate policies on

- Small Bowel Transplant-Isolated and
- Small Bowel/Liver and Multivisceral Transplant

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: TRANSPLANT-SMALL BOWEL/LIVER AND MULTIVISCERAL

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Covered; policy guidelines apply
BCNA (Medicare Advantage)	See government section.
BCN65 (Medicare Complementary)	Coinsurance covered if primary Medicare covers the service. Transportation, meals and lodging expenses related to the transplant are not covered unless specifically noted in the member's certificate/rider.

Note: *All services related to the transplant, except evaluation services, will not be authorized until the transplant is approved.*

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.